Stay updated on GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check50 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check71 days agoChange DetectedThe website has updated its contact information and principal investigators, with new entries for Joseph Martel, MD and Elise Boulanger-Scemama, MD, while removing previous contact details and designations.SummaryDifference4%
- Check100 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.